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Abstract
The adipocyte hormone leptin is thought to serve as a signal to the
central nervous system reflecting the status of fat stores. Serum leptin
levels and adipocyte leptin messenger RNA levels are clearly in-
creased in obesity. Nevertheless, the factors regulating leptin produc-
tion are not fully understood. The aim of this study was to determine
the effects of in vivo administration of the synthetic glucocorticoid
dexamethasone and weight loss on serum leptin levels in two inde-
pendent protocols. Twenty-five obese subjects were studied (18 women
and 7 men, mean age 26.6 – 6 years, BMI 31.1 – 2.5 kg/m†, %fat 40.3
– 8.3) and compared at baseline to 22 healthy individuals. Serum
levels of leptin, insulin, proinsulin and glucose were assessed at
baseline and after ingestion of dexamethasone, 4 mg per day (2 mg,
twice daily) for two consecutive days. To study the effects of weight
loss on serum leptin, 17 of the obese subjects were submitted to a low-
calorie dietary intervention trial for 8 weeks and again blood samples
were collected. Serum leptin levels were significantly higher in the
obese group compared to the control group and a high positive
correlation between leptinemia and the magnitude of fat mass was
found (r = 0.88, P<0.0001). After dexamethasone, there was a signifi-
cant increase in serum leptin levels (22.9 – 12.3 vs 51.4 – 23.3 ng/ml,
P<0.05). Weight loss (86.1 – 15.1 vs 80.6 – 14.2 kg, P<0.05) led to a
reduction in leptin levels (25.13 – 12.8 vs 15.9 – 9.1 ng/ml, P<0.05).
We conclude that serum leptin levels are primordially dependent on
fat mass magnitude. Glucocorticoids at supraphysiologic levels are
potent secretagogues of leptin in obese subjects and a mild fat mass
reduction leads to a disproportionate decrease in serum leptin levels.
This suggests that, in addition to the changes in fat mass, complex
nutritional and hormonal interactions may also play an important role
in the regulation of leptin levels.
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Introduction
The notion that genetic abnormalities con-
tribute to obesity has gained important sup-
port with the identification of the ob gene
and its protein product in 1994 (1). Leptin is
a 167-amino acid peptide produced in adi-
pose tissue in proportion to body fat and is
thought to act as an afferent satiety signal in
a feedback loop that putatively affects the
appetite and satiety centers of the brain. The
ultimate effect of this loop is to regulate
body fat mass (2,3).
In rodent models of obesity, leptin plays
a key regulatory role in energy balance via
the hypothalamus, with its action being me-
diated by specific leptin receptors (4,5). In
the arcuate nucleus, leptin interacts with neu-
ropeptide Y (NPY), which is postulated to
sense and respond to alterations in energy
balance: a decrease in NPY may result in
hypophagia and increased brown adipose
tissue activity (6). Defective production of
leptin in the ob/ob mouse produces a model
of gross obesity, severe insulin resistance
and infertility. When the mice receive leptin
they stop eating and lose weight (7). Diabe-
tes (db), another well-characterized reces-
sive obesity mutation, also results in pro-
found and early onset obesity (8). Differ-
ently from ob/ob, db/db mice are not defec-
tive in their ability to produce leptin, but
show resistance to its action (8).
Like db/db mice, humans also seem to
produce leptin normally. Some studies con-
ducted on obese humans have shown a strong
positive correlation between serum leptin
concentrations and percentage of body fat,
body mass index (BMI) and basal serum
insulin concentrations (9,10). These studies
suggest that the human adipocytes produce
leptin when the adipose mass increases and
that there is resistance to the action of leptin,
so that the increase in adipose tissue mass is
maintained.
Under normal feeding conditions, leptin
levels are strongly correlated with body fat
mass and a reduction of adiposity leads to
decreased leptinemia (10-12). Nevertheless,
in some situations such as fasting and mas-
sive overfeeding, leptin levels are down-
regulated and up-regulated independently of
changes in fat mass (13).
Furthermore, a number of hormones in-
cluding insulin, catecholamines, sexual ste-
roids and cortisol have been shown to modu-
late leptin synthesis in vitro and in vivo (14-
16). Cortisol and insulin have long been
implicated in energy balance and their inter-
action with leptin is believed to constitute a
feedback loop for the maintenance of body
weight (17). Considering the anti-obesity
action of leptin, it seems reasonable that the
hypercortisolism which classically induces
hyperphagia and obesity could be counter-
regulated by an activation of the ob gene
leading to hyperleptinemia.
The real physiological role of leptin in
humans as well as the mechanisms that regu-
late its secretion are still a matter of discus-
sion. Leptin levels are directly related to fat
mass, but other mechanisms independent of
adiposity also have a strong influence on the
serum levels of the ob gene product. The
effects of glucocorticoids on leptinemia in
humans have not been totally clarified. In
some studies, acute administration of gluco-
corticoids has raised leptinemia (16,18-21),
while in other reports such results were not
observed (14,22). In addition, only a few
studies have been performed on humans with
obesity (18,19).
In the present study we investigated the
behavior of serum leptin levels in two differ-
ent protocols: after short-term dexametha-
sone administration and after a weight re-
duction program in obese individuals. The
objective was to evaluate the influence of
each of these two factors on leptin secretion.
Patients and Methods
Twenty-five obese subjects (18 women
and 7 men, mean age 26.6 – 6 years, BMI 31.1
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– 2.5 kg/m2, %fat 40.3 – 8.3) were studied at
baseline (Table 1), after dexamethasone treat-
ment and after a weight loss program. Obesity
was defined according to the National Insti-
tutes of Health Technology Assessment Con-
ference Panel criteria (23) as BMI greater than
27.3 for women and greater than 27.8 for men,
which is approximately 120% of ideal body
weight. Blood pressure was measured in the
supine position and hypertension was consid-
ered to be present at systolic blood pressure
>140 mmHg and diastolic blood pressure >90
mmHg (24).
Twenty-two healthy individuals (15
women and 7 men, mean age 23.4 – 3.8
years, BMI 20.0 – 2.5 kg/m2, %fat 24.0 –
5.8) served as a control group for baseline
hormone comparison (Table 1). None of the
47 individuals admitted to the study were
taking any drugs or had any evidence of
metabolic disease other than obesity. Their
weight was stable for at least 3 months be-
fore the study. Anthropometric measurements
were performed on each participant, all of
them barefoot and casually dressed. Height
(m) and weight (kg) were determined to
calculate BMI as weight/height2. Waist cir-
cumference was only measured in the obese
individuals, at the narrowest point above to
the hip, and was divided by the circumfer-
ence of the hip, measured at its greatest
gluteal protuberance, to obtain the waist-to-
hip ratio. Body composition was measured
by dual energy X-ray absorptiometry (DEXA;
Hologic, Bedford, MA, USA). The study
was approved by the Ethics Committee of
Escola Paulista de Medicina, UNIFESP.
Written informed consent was obtained from
all subjects before their participation in the
study.
Baseline evaluation
Obese group. After a 12-h overnight fast,
blood was drawn for the determination of
serum leptin, glucose, insulin, proinsulin and
cortisol. Renal, hepatic and thyroid func-
tions were also assessed. The oral glucose
tolerance test was performed to ascertain
that the obese subjects were nondiabetic.
Normal glucose tolerance was defined ac-
cording to the new World Health Organiza-
tion criteria and ADA Committee Report
(25,26). Anthropometric measurements were
made and body composition was assessed by
DEXA.
Control group. After a 12-h overnight
fast, blood was drawn for leptin, insulin and
proinsulin analysis. Anthropometric meas-
urements were made and body composition
was assessed by DEXA.
Dexamethasone protocol. Dexametha-
sone was administered twice daily at the
dose of 2 mg for two days (total dose, 8 mg).
On the following morning, after a 12-h fast,
blood samples were drawn for leptin, insu-
lin, proinsulin, cortisol and glucose analysis.
Weight reduction protocol. Seventeen of
the 25 obese individuals were submitted to a
weight reduction program. They were in-
structed to follow a diet containing 1000
kcal less than the calculated daily energy
requirements for each individual (55%
carbohydrates, 15% protein, 30% fat) for
8 weeks. After this period, samples were
drawn for leptin, insulin and proinsulin anal-
ysis. Anthropometric measurements were
made and body composition was assessed
again.
Table 1 - Clinical and anthropometric parameters
of the obese and control groups.
Data are reported as means ± SD. *P<0.03 for
age, BMI, fat mass and %fat (independent
samples t-test).
Obese Control
N 25 22
Sex (female/male) 18/7 15/7
Age (years) 26.6 ± 6.0* 23.4 ± 3.8
BMI (kg/m²) 31.1 ± 2.5* 20.0 ± 2.5
Fat mass (kg) 31.8 ± 5.8* 12.9 ± 3.5
%Fat 40.3 ± 8.3* 24.0 ± 5.8
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Assays
Leptin, specific insulin and proinsulin
were measured in duplicate using commer-
cial radioimmunoassay kits (Linco Research
Inc., St. Charles, MO, USA). For insulin the
limit of sensitivity was 2 µIU/ml and the
intra- and interassay coefficients of variation
were <10%. Cross-reactivity was <0.2% with
human proinsulin and 100% with human
insulin. Normal fasting range: 5-15 µIU/ml.
For the proinsulin assay the limit of sensitiv-
ity was 2 pM/ml and intra- and interassay
coefficients of variation were <10%. Cross-
reactivity with human insulin and human C
peptide was <0.1%. Leptin radioimmunoas-
say using a polyclonal antibody raised in
rabbits against highly purified recombinant
human leptin (27) presented coefficients of
variation for within and between analyses
ranging from 3.6 to 8.2% and from 3.5 to
6.1%, respectively. Serum glucose was de-
termined by an enzymatic method, using a
Selectra 2 glucose analyzer (Merck S.A.,
Rio de Janeiro, RJ, Brazil). Cortisol was also
measured in duplicate using a specific radio-
immunoassay.
Statistical analysis
Statistical analysis was performed using
the SPSS program, version 7.0 for Windows
95 (SPSS Inc., Chicago, IL, USA). The obese
and control group variables were compared
by the t-test for independent samples. The
correlation between leptin and other vari-
ables was established using the Pearson cor-
relation test. Data obtained at baseline, after
dexamethasone and after weight loss were
compared by the Student t-test. Results are
reported as means – SD. Differences were
accepted as significant at P<0.05.
Results
Baseline evaluations
The levels of leptin (22.9 – 12.3 vs 5.7 –
3.2 ng/ml), P<0.0001), insulin (25.8 – 16.1
vs 16.3 – 8.4 µIU/ml, P = 0.01) and proinsu-
lin (15.9 – 11.4 vs 9.0 – 2.8 pM/ml), P =
0.006) were significantly higher in the obese
group compared to the control group. Base-
line plasma leptin levels correlated highly
with the percentage of fat (r = 0.88,
P<0.0001). Fasting and after load glucose
levels were 89.8 – 5.7 and 99.2 – 26.1 mg/dl,
respectively, in obese individuals. A signifi-
cant correlation was also observed with BMI
(r = 0.68, P<0.0001), insulin (r = 0.29, P =
0.048) and proinsulin (r = 0.4, P = 0.005).
Baseline leptin levels were three-fold higher
in women than in men (P<0.0001). Never-
theless, when the data were adjusted for fat
percentage the difference was no longer sig-
nificant.
Dexamethasone protocol
Dexamethasone administration sup-
pressed endogenous cortisol in all subjects,
indicating good compliance with the proto-
col (Table 2). No adverse effects or weight
change (85.1 – 15.2 vs 85.4 – 15.1 kg, P =
0.96, before and after dexamethasone, re-
spectively) were observed. Leptin levels in-
creased significantly (Table 2) and the mag-
nitude of serum leptin elevation (absolute
variation in leptin levels) was dependent on
increasing body fat mass values (r = 0.68,
Table 2 - Serum glucose, leptin, insulin, proinsulin
and cortisol levels before and after dexametha-
sone administration to obese individuals.
Data are reported as means ± SD. *P<0.003 com-
pared to baseline (Student t-test).
Baseline After
dexamethasone
Glucose (mg/dl) 89.8 ± 5.7 104.6 ± 16.6*
Leptin (ng/ml) 22.9 ± 12.3 51.4 ± 23.3*
Insulin (µIU/ml) 25.8 ± 16.1 57.8 ± 32.6*
Proinsulin (pM/ml) 15.9 ± 11.4 32.5 ± 28.0*
Cortisol (µg/dl) 15.8 ± 9.2 0.8 ± 0.5*
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P<0.0001) (Figure 1). Serum levels of insu-
lin, proinsulin and glucose were also signif-
icantly increased (Table 2). One male sub-
ject presented fasting glucose at diabetic
levels (177 mg/dl) after the use of dexameth-
asone, which normalized within a short term.
No correlation was established between
the change in insulin, proinsulin and glucose
levels after dexamethasone and leptin varia-
tion (r = 0.21, P = 0.3; r = 0.07, P = 0.75; r =
0.17, P = 0.43, respectively). Plasma insulin
variation after dexamethasone was corre-
lated with waist circumference and waist-to-
hip ratio; however, such correlation was only
significant in relation to waist circumference
(r = 0.4, P = 0.047; r = 0.35, P = 0.09,
respectively). Leptin variation after dexa-
methasone tended to be greater in women
(31.5 – 12.5 ng/ml) than in men (20.5 – 14.8
ng/ml), but the difference was not statisti-
cally significant (P = 0.07).
Weight reduction protocol
There was a significant weight and body
fat mass reduction (Table 3). Weight loss
was mostly explained by fat mass reduction.
However, a significant decrease in lean body
mass was also observed (Table 3). BMI,
waist circumference and diastolic blood pres-
sure also decreased significantly (Table 3).
Serum leptin showed a significant 36.6%
decrease from baseline values (Table 3).
Serum insulin and proinsulin levels also de-
creased after weight loss, but the difference
was not statistically significant (Table 3).
The BMI and fat mass variations were sig-
nificantly correlated with leptin change after
weight loss (r = 0.55, P = 0.02; r = 0.63, P =
0.006, respectively).
Discussion
Our data clearly show that obese indi-
viduals have increased serum leptin, insulin
and proinsulin levels when compared to a
non-obese group.
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Figure 1 - Increase in serum leptin after dexamethasone treatment. Leptin variation was
plotted against basal fat mass for 25 obese subjects.
Table 3 - Clinical, anthropometric and hormonal parameters of obese subjects submit-
ted to a weight loss program, at baseline and after weight loss.
Data are reported as means ± SD. BMI, Body mass index; WHR, waist-to-hip ratio;
SBP, systolic blood pressure; DBP, diastolic blood pressure; NS, not significant.
Baseline After weight loss P value
Weight (kg) 86.1 ± 15.1 80.6 ± 14.2 <0.05
BMI (kg/m²) 31.6 ± 2.7 29.6 ± 2.7 <0.05
Waist (cm) 94.8 ± 9 89.5 ± 9.4 <0.05
WHR 0.87 ± 0.04 0.86 ± 0.03 NS
SBP (mmHg) 133.2 ± 16.6 126.7 ± 13.6 NS
DBP (mmHg) 88.2 ± 11.6 80.8 ± 8.1 <0.05
%Fat 40.7 ± 8.1 39.6 ± 8.1 <0.05
Fat mass (kg) 32.6 ± 6.1 29.3 ± 5.3 <0.0001
Lean body mass (kg) 48.7 ± 12.9 47.6 ± 12.2 <0.05
Insulin (µIU/ml) 27.2 ± 17.6 20.2 ± 6.4 NS
Leptin (ng/ml) 25.1 ± 12.8 15.9 ± 9.1 <0.05
Proinsulin (pM/ml) 14.1 ± 9.9 11.1 ± 3.8 NS
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Leptin levels were significantly corre-
lated with fat mass magnitude, plasma insu-
lin and proinsulin. This is in accordance with
other studies (28,29), including a Brazilian
one by Pardini et al. (30). However, in a
South Asian population leptin levels were
not correlated with insulin and proinsulin,
showing an ethnic variation in this associa-
tion due to unknown reasons (31). The asso-
ciation between hyperleptinemia and hyper-
insulinemia is a characteristic of obesity and
both conditions reflect a state of hormone
resistance. Recent studies on adipocyte cell
lines and on animal models of obesity have
shown that insulin stimulates leptin gene
expression (32,33). In contrast, in humans
the effect of insulin on plasma leptin is more
controversial. Short-term insulinemia, such
as after food intake, has not been demon-
strated to affect leptin levels, unless the acute
hyperinsulinemia is extended beyond 48 h
(5).
Concerning the glucocorticoid protocol,
our data have shown that after a two-day
administration of supraphysiological doses
of dexamethasone there was over a two-fold
increase (124%) in leptin without any change
in body weight. Most studies carried out to
determine the effects of dexamethasone on
leptinemia were performed in non-obese in-
dividuals and in general led to increases in
leptinemia (16,20,21,34,35). Two studies
involved obese populations (18,19). Kiess et
al. (18) administered 1.5 mg/m2 of dexa-
methasone to obese children and obtained a
26.3% increase in leptinemia. Dagogo-Jack
et al. (19) observed a 75% elevation in
leptinemia in an older population (mean age
41.9 – 4.0 years) after 10 mg of dexametha-
sone with similar responses in both sexes.
Our results showed a greater leptinemia re-
sponse, with women tending to show higher
variation. We suggest that this difference in
serum leptin change after dexamethasone
between sexes might be due to the predomi-
nance of subcutaneous fat mass in women
which was shown to produce more leptin
than the visceral adipose tissue (36).
In other studies, however, dexametha-
sone was shown to decrease leptin gene
expression in mouse adipocytes (37), and
methylprednisolone reportedly had no effect
on leptin secretion (22). A very important
result of the present study is that leptinemia
was substantially increased after dexameth-
asone administration, independent of any
variation in body weight. Our study has defi-
nitely shown that dexamethasone adminis-
tered for two days at supraphysiologic doses
to obese individuals can increase leptin se-
cretion. In spite of the high basal leptinemia
that usually accompanies the high percent-
age of fat in obese individuals, this signifi-
cant rise in leptin levels after dexamethasone
demonstrates that the adipocytes were not at
their maximum capacity to secrete leptin.
However, the mechanism by which dexa-
methasone stimulates leptin release, whether
by a direct action on the ob gene or via
induced hyperinsulinemia, still remains con-
troversial.
We did not find any significant correla-
tion between leptin and insulin variation
after dexamethasone, a fact that might sug-
gest that leptin levels were increased by a
direct action of glucocorticoids on the ob
gene rather than induced by hyperinsuline-
mia. Nevertheless, it is possible that the dou-
bling of fasting insulin levels induced by
dexamethasone contributed to the increase
in leptinemia observed. As shown by vari-
ous studies, the parallel rise in leptin mRNA
levels and serum leptin levels after dexa-
methasone administration in vivo and in vi-
tro strongly suggests that the effect is medi-
ated at the mRNA level (15,16,18,21).
Kolaczynski et al. (16), however, unex-
pectedly observed unchanged ob gene ex-
pression after ingestion of 10 mg dexameth-
asone despite a doubling of serum leptin
levels. In their study, short-term clamped
hyperinsulinemia had no additional effect
on the elevation of leptin. The study by
Larsson and AhrØn (20) showed a rise in
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leptin levels after 15 mg of dexamethasone
independent of the degree of change in insu-
lin sensitivity, suggesting that the effect of
dexamethasone could be a direct result of
the steroid on ob gene expression in adipose
tissue. Another interesting study by Berneis
et al. (35) found an increase in leptin levels
after treatment with growth hormone and
glucocorticoids, despite a decrease in body
fat. This suggested that serum leptin is regu-
lated by glucocorticoids, possibly through
changes in insulin secretion, independent of
variations in body fat mass.
As discussed by Papaspyrou-Rao et al.
(21), additional studies of the time course of
the effects of glucocorticoid and insulin dur-
ing clamped conditions are needed to deter-
mine whether dexamethasone stimulates
leptin without concomitant hyperinsuline-
mia, how rapidly this effect occurs, and if
there are gender- or obesity-related differ-
ences in responsiveness to these hormones.
It is of great importance to better understand
the interaction among glucocorticoids, insu-
lin and leptin since glucocorticoids and insu-
lin are major antagonistic long-term regula-
tors of energy balance (17) and leptin is a
sensing parameter for the adipose tissue that
putatively acts as a satiety factor. The obser-
vation that dexamethasone, even at physi-
ological doses, potently induced ob gene
expression suggests that glucocorticoids are
involved physiologically in the regulation of
leptin secretion in vivo (34). A loop system
might be envisioned in which food intake
could trigger insulin and glucocorticoid out-
put, thereby favoring fat accumulation and
the secretion of leptin, subsequently causing
satiation (2).
Our data also showed an out-of-propor-
tion fall in leptin levels (36.6%) in relation to
a mild weight loss (6.4%). Considine et al.
(10) found a reduction in serum leptin con-
centration of about 53% in seven individuals
after a 10% body weight loss. Other authors
obtained similar results regarding a dramatic
decrease in leptin concentration, without a
comparable alteration in BMI or fat mass
(11,12). This suggests that a relative defi-
ciency in leptin may cause an increase in
appetite and a decrease in energy expendi-
ture, in accordance with the effects of leptin
deficiency observed in animals. This hypo-
thesis could explain, at least in part, the high
rate of relapse after weight reduction and the
increased hunger and decreased energy ex-
penditure in this situation (38). To date,
there is no definitive answer about the factor
responsible for the out-of-proportion de-
crease in serum leptin. It seems that, besides
the variation in fat mass, the plasma leptin
concentration after weight loss is also con-
trolled by nutritional and hormonal factors.
According to Geldszus et al. (12), a low-
calorie diet itself seems unlikely to explain
the out-of-proportion fall in leptin levels. In
the cited study, an unrestricted diet follow-
ing a weight reduction program did not ex-
plain the difference in serum leptin com-
pared to the control subjects who never lost
weight. However, another study demon-
strated that the fall in serum leptin during
fasting can be prevented by infusion of small
amounts of glucose, suggesting that leptin
release might have been influenced by se-
rum insulin (13). In our patients, we ob-
served a reduction in insulin levels after
weight loss, which, however, was not statis-
tically significant. Nor did we find any cor-
relation between leptin and insulin reduction
after weight loss.
An evolutionary theory proposed by Flier
(39) hypothesizes that a potent anti-obesity
adipostatic system would be selected under
conditions of food scarcity. Thus, according
to this theory, the dominant role of leptin
would be triggering neuroendocrine re-
sponses when its plasma levels are decreased.
The out-of-proportion fall in leptin levels
during a low-calorie diet would be a signal to
the brain of energy insufficiency and of the
need to activate compensatory responses.
The anti-obesity action of leptin in humans,
however, has already been described in two
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children with a homozygous mutation in the
leptin gene and severe obesity (40). This
indicates that leptin is also important as a
factor to avoid hyperphagia and weight gain.
We hope that further studies will expand our
understanding concerning the kinetics of
leptin secretion that appears to be extremely
susceptible to up- and down-regulation by
fat mass-dependent and fat mass-independ-
ent factors.
We conclude that plasma leptin levels are
primordially dependent on fat mass magni-
tude. Glucocorticoids are potent secreta-
gogues of leptin in obese individuals. A mild
fat mass reduction leads to an out-of-propor-
tion decrease in serum leptin levels. This
suggests that, in addition to the changes in
fat mass, complex nutritional and hormonal
interactions may also play an important role
in the regulation of leptin levels.
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